CD19 and diffuse large B-cell lymphoma: AUTO3, anti-CD19/CD22 CAR-T treatment, with or without pembrolizumab, has demonstrated an ORR of 64% and a CR of 55% in a phase I/II study of relapsed refractory DLBCL [70].